J. M. Sanchez

667 total citations
15 papers, 499 citations indexed

About

J. M. Sanchez is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, J. M. Sanchez has authored 15 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in J. M. Sanchez's work include Lung Cancer Treatments and Mutations (6 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Lung Cancer Research Studies (3 papers). J. M. Sanchez is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Lung Cancer Research Studies (3 papers). J. M. Sanchez collaborates with scholars based in Spain, United States and Italy. J. M. Sanchez's co-authors include Bartomeu Massutí, Luis Paz‐Ares, A. García, Guillermo López-Vivanco, Mariano Provencio, María L. Amador, Rafael Rosell, Ana Fernández Montés, Miguel Quintela-Fandiño and Silvana Mourón and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cell Reports.

In The Last Decade

J. M. Sanchez

15 papers receiving 483 citations

Peers

Countries citing papers authored by J. M. Sanchez

Since Specialization

Citations

This map shows the geographic impact of J. M. Sanchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. M. Sanchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. M. Sanchez more than expected).

Fields of papers citing papers by J. M. Sanchez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. M. Sanchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. M. Sanchez. The network helps show where J. M. Sanchez may publish in the future.

Co-authorship network of co-authors of J. M. Sanchez

This figure shows the co-authorship network connecting the top 25 collaborators of J. M. Sanchez. A scholar is included among the top collaborators of J. M. Sanchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. M. Sanchez. J. M. Sanchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes 2022 ·Nature Communications ·(unknown), (unknown), Stephan Hütter, Carmelo Gurnari, J. M. Sanchez, Janet Wang, Yimin Huang, (unknown), (unknown), Wanying Xu, (unknown), (unknown), Babal K. Jha, Mehmet Koyutürk, Jaroslaw P. Maciejewski, Torsten Haferlach, Thomas LaFramboise	28
2	PL 02.04 SCAT Ph III Trial: Adjuvant CT Based on BRCA1 Levels in NSCLC N+ Resected Patients. Final Survival Results a Spanish Lung Cancer Group Trial 2017 ·Journal of Thoracic Oncology ·Bartomeu Massutí, Manuel Cobo, (unknown), Iván Ballesteros, Teresa Morán, R. Arrabal, J.L. González-Larriba, I. Barneto, (unknown), Javier de Castro, Santiago Ponce-Aix, C. Baamonde, Miguel Ángel Suárez Muñóz, Guillermo López-Vivanco, Juan José Rivas de Andrés, Dolores Isla, (unknown), J. M. Sanchez, José Sánchez–Payá, R. Rosell	5
3	Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors 2016 ·Current Drug Targets ·María J. Bueno, J. M. Sanchez, Rámón Colomer, Miguel Quintela-Fandiño	4
4	Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics 2016 ·Cell Reports ·Paloma Navarro, María J. Bueno, (unknown), (unknown), J. M. Sanchez, Silvana Mourón, Javier Muñoz, Gonzalo Goméz-López, (unknown), Francisca Mulero, Navdeep S. Chandel, Miguel Quintela-Fandiño	78
5	Monitoring vascular normalization induced by antiangiogenic treatment with 18F‐fluoromisonidazole‐PET 2015 ·Molecular Oncology ·(unknown), (unknown), María Luisa Soto‐Montenegro, Diego Megı́as, Silvana Mourón, J. M. Sanchez, Manuel Hidalgo, Pedro P. López‐Casas, Francisca Mulero, Manuel Desco, Miguel Quintela-Fandiño	34
6	Other targeted drugs in melanoma. 2015 ·PubMed ·María González‐Cao, Jordi Rodón, Niki Karachaliou, J. M. Sanchez, Mariacarmela Santarpía, Santiago Viteri, Sara Pilotto, Cristina Teixidó, (unknown), R. Rosell	12
7	Outcome of patients with syncope beyond the implantable loop recorder 2012 ·EP Europace ·Pilar Merlos, Eva Rúmiz, Ricardo Ruiz‐Granell, (unknown), Maite Izquierdo, (unknown), Eloy Domínguez, J. M. Sanchez, Salvador Morell, Roberto García–Civera	8
8	SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer. 2011 ·Journal of Clinical Oncology ·Bartomeu Massutí, Ulpiano Jiménez, J.M. Rodríguez Paniagua, (unknown), Manuel Cobo, Enric Carcereny, R. Arrabal, (unknown), I. Barneto, R. de las Peñas, C. Baamonde, (unknown), J.L. González-Larriba, Guillermo López-Vivanco, Florentino Hernándo, (unknown), Á. Artal, (unknown), R. Rosell, J. M. Sanchez, (unknown)	1
9	Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. 2011 ·Journal of Clinical Oncology ·Enric Carcereny, Matias Molina, José Javier Sánchez, Jordi Bertrán-Alamillo, Carlos Mayo, Erika Aldeguer, Ana Giménez‐Capitán, (unknown), Carlota Costa, Salvador Benlloch, (unknown), Cristina Bugés, (unknown), (unknown), Manuel Dómine, Mariano Provencio, J. M. Sanchez, Carlos Camps, Miquel Tarón, R. Rosell	8
10	Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. 2011 ·Journal of Clinical Oncology ·R. Rosell, R. Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, F. Cardenal, Ramón García Gómez, Cinta Pallarés, J. M. Sanchez, R. Porta, M. Cobo, (unknown), Pilar Garrido, Amelia Insa, Filippo de Marinis, (unknown), (unknown), Enric Carcereny, Miquel Tarón, Luis Paz‐Ares, (unknown)	110
11	21LBA Assessing the value of preoperative chemotherapy in early-stage non-small cell lung cancer: mature data and prognostic factors analysis of a Phase III randomized trial of surgery alone vs preoperative Paclitaxel/Carboplatin (PC) vs postoperative PC. Final NATCH data. A Spanish Lung Cancer Group Trial 2009 ·European Journal of Cancer Supplements ·Bartomeu Massutí, J. M. Sanchez, G. Alonso, J Maestre, J.L. González-Larriba, Carlos Camps, José Manuel Rodríguez-Paniagua, Enriqueta Felip, (unknown), R. Rosell	3
12	A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) 2006 ·Journal of Clinical Oncology ·Luis Paz‐Ares, J. M. Sanchez, A. García, Bartomeu Massutí, Guillermo López-Vivanco, Mariano Provencio, Ana Fernández Montés, (unknown), María L. Amador, Rafael Rosell	125
13	Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial 2006 ·Journal of Clinical Oncology ·Mark A. Socinski, Silvia Novello, J. M. Sanchez, (unknown), Ramaswamy Govindan, Chandra P. Belani, JN Atkins, (unknown), (unknown), Richard C. Chao	79
14	A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC) 2004 ·Journal of Clinical Oncology ·(unknown), J. M. Sanchez, Petr Zatloukal, Michael C. Perry, John Hamm, Chandra P. Belani, (unknown), Johan Vansteenkiste, Eudald Felip, (unknown)	2
15	XPC, XPD/ERCC2, UMPS, CYP1b1 and XRCC5, single nucleotide polymorphisms (SNPs) in head and neck cancer 2004 ·Journal of Clinical Oncology ·Joan Carles, Mariano Monzó, Rosa Artells, Mercedes Amat, P. Foro, (unknown), F. Alameda, J. M. Sanchez, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact